|
|
|
|
|
|
|
The 2026 Southeastern Section of the American Urological Association Annual Meeting
|
|
|
|
|
| Pathways for Prostate Cancer Evaluation: Guidelines, Tools, and Best Practices to Optimize PSA Based Screening
|
| Sanoj Punnen, MD
|
| PSA-based screening for prostate cancer reduces mortality, with the benefit growing over time, and Dr. Punnen emphasized starting screening around age 45–50 and tailoring frequency to PSA level and life expectancy. He also highlighted that mpMRI, biomarkers, and newer tools like PSMA PET/CT can better select men for biopsy and reduce unnecessary procedures, while AI and next-generation imaging may further refine screening in the future.
|
|
|
|
|
|
| PSA and Alkaline Phosphatase Decline in the EORTC-1333 PEACE-3 Study Evaluating the Addition of Radium-223 in mCRPC Starting Enzalutamide
|
| Murilo de Almeida Luz, MD
|
| Adding six cycles of radium‑223 to enzalutamide in PEACE‑3 led to faster and deeper biomarker responses in bone‑metastatic mCRPC, especially for PSA ≥90% declines and alkaline phosphatase reduction/normalization. These improved PSA and ALP kinetics align with the trial’s previously reported PFS and OS benefit, supporting the combination as a stronger first‑line option than enzalutamide alone.
|
|
|
|
|
|
| Darolutamide Plus Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer: Efficacy and Safety by Disease Volume in the Phase 3 ARANOTE Study
|
| Zachary Klaassen, MD, MSc
|
| In the ARANOTE post hoc analysis, darolutamide plus ADT improved outcomes in mHSPC across both high- and low-volume disease, with an especially large relative benefit in low-volume patients. It delayed progression to mCRPC, slowed PSA progression, increased undetectable PSA rates, and maintained a favorable safety profile without adding meaningful toxicity.
|
|
|
|
|
|
| Treatment of UTUC with UGN-101: Baseline Characteristics from the uTRACT Registry Study for UGN-101
|
| Marc Bjurlin, DO, MSc, FACOS
|
| The uTRACT registry is capturing real‑world UGN‑101 use in a more heterogeneous UTUC population than the pivotal OLYMPUS trial, including antegrade administration, high‑grade disease, and less restrictive residual disease criteria. In the first 203 treated participants, most were male, White, and ECOG 0, with the renal pelvis the most common tumor location and roughly two‑thirds having complete or partial ablation before UGN‑101 induction.
|
|
|
|
|
|
|
|
|
|
|
| Impact of Cytoreductive Nephrectomy for RCC with Tumor Thrombus: Results from the Intercontinental Collaboration of RCC
|
| Maxwell Sandberg, MD
|
| In this ICORCC retrospective study of 131 patients with metastatic RCC and tumor thrombus treated with cytoreductive nephrectomy plus thrombectomy, outcomes remained poor: median 5-year OS was 1.7 years, CSS 2.2 years, and PFS 1.1 years. Worse survival was linked to systemic symptoms, larger primary tumors, adrenal metastases, and brain metastases, suggesting any benefit from surgery is concentrated in carefully selected patients and needs prospective validation.
|
|
|
|
|
|
| Assessing the Role of Girentuximab PET/CT in Clinical Decision-Making: Results from a National Survey of Urologic Oncologists
|
| Gianpaolo Carpinito, MD
|
| In this national survey, urologic oncologists said girentuximab PET/CT would most change management when scans were PET‑avid, especially by shifting decisions about biopsy or surgery in indeterminate or complex renal masses. Non‑PET‑avid results led to fewer management changes and less concordance in advanced RCC scenarios, suggesting clinicians are still cautious about relying on a negative scan in metastatic or post‑treatment settings.
|
|
|
|
|
|
| Patient Time Toxicity from Management Options for NMIBC
|
| Veerain Gupta, MD
|
| Among Medicare beneficiaries with NMIBC, time toxicity was highest with cystectomy and intravesical therapies compared with TURBT alone, based on healthcare contact days in the year after diagnosis. In the analysis, median contact days were 15 for TURBT alone, 17 for BCG, 19 for intravesical chemotherapy, and 34 for radical cystectomy, with cystectomy adding the most adjusted contact days.
|
|
|
|
|
|
| Response to Treatment with UGN-102 in Patients with Early or Late Recurrent Low-Grade Intermediate Risk NMIBC
|
| William Huang, MD
|
| UGN-102 produced a high complete response rate in recurrent low-grade intermediate-risk NMIBC, and response durability looked similar whether the prior recurrence was early or late. In the SESAUA analysis, CR at 3 months was 77.4% in the early-recurrence group and 81.9% in the late-recurrence group, with 12- and 24-month response probabilities also closely aligned between groups.
|
|
|
|
|
|
| Implementation of Patient Reported Outcomes as a NMIBC Clinical Trial Endpoint
|
| Spencer Bell, MD
|
| Only a minority of NMIBC interventional trials have incorporated patient-reported outcomes as endpoints, despite FDA emphasis on capturing symptom burden and patient experience. In this review of 94 trials, 21 included PROs, most often using EORTC QLQ-C30 and EORTC QLQ-NMIBC24, and PRO use appeared more common in larger, randomized studies than in smaller or nonrandomized trials.
|
|
|
|
|
|
|
|
|
|
|
